Salvage chemotherapy with dexamethasone, etoposide, ifosfamide and cisplatin (DVIP) for relapsing and refractory non-Hodgkin's lymphoma

Israel Medical Association Journal

Volumn 11, Issue 1, 2009, Pages 16-22

  Lazar, Ariela Dortort ^a,b   Shpilberg, Ofer ^a   Shaklai, Mati ^a   Bairey, Osnat ^a  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Non hodgkin's lymphoma; Relapse; Salvage chemotherapy; Stem cell transplantation

Indexed keywords

BLEOMYCIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; LACTATE DEHYDROGENASE; METHOTREXATE; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; DICE PROTOCOL;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; EVENT FREE SURVIVAL; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; LARGE CELL LYMPHOMA; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PROGNOSIS; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; SURVIVAL TIME; TUMOR BIOPSY; MIDDLE AGED; MORTALITY; SURVIVAL; TREATMENT FAILURE; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEXAMETHASONE; ETOPOSIDE; FEMALE; HUMANS; IFOSFAMIDE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TREATMENT FAILURE;

EID: 65349173544     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-6.
2. Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71: 117-22.
3. Cabanillas F, Hagemeister F, McLaughlin P, et al. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 1987; 5: 407-12.
4. Wilson WH, Bryant G, Bates S, et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1573-82.
5. Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP - an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994; 12: 1169-76.
6. Rodriguez MA, Cabanillas FC, Velasquez W, et al. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol 1995; 13: 1734-41.
7. Goss P, Shepherd F, Scott JG, Baker M, Sutton D, Sutcliffe S. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) as salvage therapy in non-Hodgkin's lymphomas. Leuk Lymphoma 1995; 18: 123-9.
8. Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3776-85.
9. Rodriguez-Monge E, Cabanillas F. Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience. Hematol Oncol Clin North Am 1997; 11: 937-47.
10. Guglielmi C, Gomez F, Philip T, Hagenbeek A, Martelli M, Sebban C. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol 1998; 16: 3264-9.
11. Hagemeister FB. Treatment of relapsed aggressive lymphomas: regimens with and without high dose therapy and stem cell rescue. Cancer Chemother Pharmacol 2002; 49(Suppl 1): S13-20.
12. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-5.
13. Haim N, Rosenblatt E, Wollner M, Ben-Shahar M, Epelbaum R, Robinson E. Salvage therapy for non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide and cisplatin. Cancer Chemother Pharmacol 1992; 30(3): 243-4.
14. Haim N, Ben-Shahar M, Faraggi D, Tsuri-Etzioni A, Leviov M, Epelbaum R. Dexamethasone, etoposide, ifosfamide and cisplatin as second-line therapy in patients with aggressive non-Hodgkin's lymphoma. Cancer 1997; 80: 1989-96.
15. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airline House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835-49.
16. The International Non-Hodgkin's Lymphoma Prognostic Factor Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-94.
17. Solal-Celigny P, Roy P, Colombat P, White J, Armitage J, Montsarrat E. Follicular Lymphoma International Prognostic Index. Blood 2004; 104: 1258-65.
18. Vose JM, Zhang MJ, Rowlings PA, et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001; 19: 406-13.
19. Seyfarth B, Josting A, Dreyling M, Schmitz N. Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large B-cell lymphoma and Hodgkin disease. Br J Haematol 2006; 133: 3-18.
20. Blay J, Gomez F, Sebban C, et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood 1998; 92: 3562-8.
21. Guglielmi C, Martelli M, Federico M, et al., Italian Intergroup for Lymphomas. Risk-assessment in diffuse large cell lymphoma at first relapse. A study by the Italian Intergroup for Lymphomas. Haematologica 2001; 86: 941-50.
22. Hamlin PA, Zelenetz AD, Kewalramani T, et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003; 102: 1989-96.
23. Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as secondline therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004; 103: 3674-88.
24. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-42.
25. Pfreundschuh M, Truemper L, Kloess M, et al., German High-Grade Non-Hodgkin's Lymphoma Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphoma: results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104: 634-41.